04 Jan 2023
Thermo Fisher Scientific Inc. (Waltham, MA; USA) has completed its acquisition of The Binding Site Group (Birmingham, UK) in an all-cash transaction valued at GBP 2.3 billion, or USD 2.8 billion at current exchange rates.
Más info
20 Jan 2022
Oncocyte Corporation (Irvine, CA, USA) has entered into a development and co-marketing agreement for two distributed in vitro diagnostic (IVD) assays on Thermo Fisher Scientific’s (Waltham, MA, USA) Ion Torrent Genexus System. The agreement also grants Oncocyte rights to develop future companion diagnostics on the Genexus System.
Más info
22 Sep 2021
Thermo Fisher Scientific Inc. (Waltham, MA, USA) has launched the world’s first fully integrated digital PCR (dPCR) system designed to provide highly accurate and consistent results within 90 minutes.
Más info
20 Jan 2021
Thermo Fisher Scientific Inc. (Waltham, MA, USA) has entered into a definitive agreement to acquire Mesa Biotech (San Diego, CA, USA), a privately held molecular diagnostic company, for approximately USD 450 million in cash.
Más info
05 Mar 2020
Thermo Fisher Scientific Inc. (Waltham, MA, USA) has announced that it plans to acquire QIAGEN N.V. (Venlo, Netherlands), a provider of molecular diagnostics and sample preparation technologies. Thermo Fisher's boards of directors and the managing board of QIAGEN have unanimously approved Thermo Fisher's proposal to acquire QIAGEN.
Más info
03 Oct 2017
Thermo Fisher Scientific’s liquid chromatography mass spectrometry (LC-MS) in vitro diagnostic (IVD) systems, which enable the quantitation of analytes in complex matrices, have received registration by Brazil’s National Health Surveillance Agency (ANVISA), allowing clinical laboratories in the country to now screen and quantify drugs efficiently.
Más info